$2.76 Billion is the total value of Rock Springs Capital Management LP's 135 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 40.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $104,296,000 | -11.6% | 605,000 | -13.6% | 3.77% | -17.1% |
| ONCE | Sell | SPARK THERAPEUTICS INC | $51,740,000 | -15.5% | 505,371 | -6.0% | 1.87% | -20.7% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $49,384,000 | +23.9% | 325,000 | -2.8% | 1.79% | +16.3% |
| MOH | Sell | MOLINA HEALTHCARE INC | $29,487,000 | +0.1% | 206,000 | -0.7% | 1.07% | -6.1% |
| NVTA | Sell | INVITAE CORP | $26,438,000 | -1.8% | 1,125,000 | -2.2% | 0.96% | -7.9% |
| ODT | Sell | ODONATE THERAPEUTICS INC | $15,777,000 | +60.4% | 430,000 | -3.4% | 0.57% | +50.7% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $15,523,000 | -23.9% | 410,000 | -21.5% | 0.56% | -28.5% |
| CVET | Sell | COVETRUS INC | $788,000 | -96.2% | 32,231 | -95.0% | 0.03% | -96.4% |
| HRTX | Sell | HERON THERAPEUTICS INC | $558,000 | -93.5% | 30,000 | -91.4% | 0.02% | -93.9% |
| SLDB | Exit | SOLID BIOSCIENCES INC | $0 | – | -60,000 | -100.0% | -0.02% | – |
| NVAX | Exit | NOVAVAX INC | $0 | – | -3,250,000 | -100.0% | -0.07% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS | $0 | – | -700,000 | -100.0% | -0.22% | – |
| CMTA | Exit | CLEMENTIA PHARMACEUTICALS IN | $0 | – | -275,000 | -100.0% | -0.28% | – |
| IFRX | Exit | INFLARX NV | $0 | – | -225,000 | -100.0% | -0.33% | – |
| WMGI | Exit | WRIGHT MED GROUP N V | $0 | – | -920,608 | -100.0% | -1.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.